Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy aims to shrink tumors before lung cancer surgery

NCT ID NCT05925530

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

Summary

This study is testing a treatment plan for people with a type of lung cancer that might be removable by surgery. Participants first receive a combination of immunotherapy (durvalumab) and standard chemotherapy. Doctors then decide if surgery or radiation is best, followed by more immunotherapy. The main goal is to see if this approach helps more people successfully have their tumors removed and improves long-term outcomes.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Research Site

    The Bronx, New York, 10467, United States

  • Research Site

    Houston, Texas, 77030, United States

  • Research Site

    Charlottesville, Virginia, 22908, United States

  • Research Site

    Vienna, 1130, Austria

  • Research Site

    Vienna, 1140, Austria

  • Research Site

    Kingston, Ontario, K7L 2V7, Canada

  • Research Site

    Chicoutimi, Quebec, G7H 5H6, Canada

  • Research Site

    Montreal, Quebec, H4A 3J1, Canada

  • Research Site

    Brno, 625 00, Czechia

  • Research Site

    Olomouc, 77900, Czechia

  • Research Site

    Prague, 12808, Czechia

  • Research Site

    Prague, 150 06, Czechia

  • Research Site

    La Tronche, 38700, France

  • Research Site

    Marseille, 13008, France

  • Research Site

    Montpellier, 34295, France

  • Research Site

    Mulhouse, 68070, France

  • Research Site

    Paris, 75005, France

  • Research Site

    Pessac, 33604, France

  • Research Site

    Poitiers, 86000, France

  • Research Site

    Toulouse, 31059, France

  • Research Site

    Berlin, 13125, Germany

  • Research Site

    Cologne, 51109, Germany

  • Research Site

    Großhansdorf, 22927, Germany

  • Research Site

    Moers, 47441, Germany

  • Research Site

    Würzburg, 97074, Germany

  • Research Site

    Budapest, 1122, Hungary

  • Research Site

    Törökbálint, 2045, Hungary

  • Research Site

    Bari, 70124, Italy

  • Research Site

    Bologna, 40138, Italy

  • Research Site

    Milan, 20132, Italy

  • Research Site

    Milan, 20133, Italy

  • Research Site

    Milan, 20141, Italy

  • Research Site

    Naples, 80131, Italy

  • Research Site

    Palermo, 90127, Italy

  • Research Site

    Pavia, 27100, Italy

  • Research Site

    Peschiera del Garda, 37019, Italy

  • Research Site

    Lisbon, 1350-352, Portugal

  • Research Site

    Lisbon, 1500-650, Portugal

  • Research Site

    Barakaldo, 48903, Spain

  • Research Site

    Barcelona, 08025, Spain

  • Research Site

    L'Hospitalet de Llobregat, 08908, Spain

  • Research Site

    Madrid, 28007, Spain

  • Research Site

    Madrid, 28027, Spain

  • Research Site

    Madrid, 28046, Spain

  • Research Site

    Pamplona, 31008, Spain

  • Research Site

    Valencia, 46009, Spain

  • Research Site

    Zaragoza, 50009, Spain

  • Research Site

    Solna, 171 64, Sweden

  • Research Site

    Uppsala, SE-751 85, Sweden

Conditions

Explore the condition pages connected to this study.

NON-SMALL CELL LUNG CANCER